Our research identified a higher enrichment of APOC1, LGALS1, NUSAP1, NR4A2, ADRB2 and ZNF331 in the OXPHOS pathway, in PCa with bone metastasis, suggesting that targeting these genes could potentially reverse aberrant metabolic pathways and improve treatment outcomes. The gene discussed is ADRB2; the disease is posterior cortical atrophy.